MedRise Shelf Prep

Depression Treatment Algorithm for the Psychiatry Shelf: First-Line to Next Step

On the psychiatry shelf, depression treatment questions describe at least 2 weeks of low mood or lost interest with changes in sleep, energy, appetite and concentration, then ask for the best first treatment or the next step after a drug has not worked. The question tests three decisions: have you ruled out bipolar disorder and danger, does the treatment match the severity, and do you know when to wait, raise the dose, switch or add.

The algorithm

Steps 1 to 3 come before any prescription.

  1. Confirm major depressive disorderFive or more of nine symptoms for at least 2 weeks, one of them depressed mood or loss of interest, with impaired function. Any past manic or hypomanic episode means a bipolar disorder, not MDD, and antidepressant monotherapy should be avoided in bipolar I.
  2. Rule out medical and substance causesCheck a CBC, metabolic panel, TSH with free T4 and a toxicology screen, adding other tests as the history suggests. These exclude medical illness that can look like depression.
  3. Assess suicide risk and choose the settingAsk directly about ideation, plan and intent. Ideation with intent to act, or psychotic symptoms, often warrants inpatient care.
  4. Grade severity and pick the first treatmentMild: structured psychotherapy such as CBT is preferred. Moderate: CBT or a second-generation antidepressant (SSRI, SNRI, bupropion, mirtazapine and others) alone, or both together. Severe without psychosis: medication, ideally combined with psychotherapy; psychotherapy alone is not enough.
  5. Treat psychotic, catatonic or life-threatening features differentlyPsychotic features: an antidepressant plus an antipsychotic, or ECT; hold structured psychotherapy until the psychosis settles. ECT can be first-line for psychotic or catatonic features, severe suicidal ideation, refusal to eat or drink, or a deteriorating physical condition. Benzodiazepines are the other option for catatonia.
  6. Choose the drug by side effects and safetySSRIs are the usual first drug; antidepressants work about equally well but differ in side effects. Bupropion, mirtazapine and vortioxetine cause fewer sexual side effects. Mirtazapine adds drowsiness, appetite and weight gain. Bupropion is approved for smoking cessation but is contraindicated with a seizure disorder, bulimia or anorexia. TCAs are second-line and dangerous in overdose; MAOIs are third-line.
  7. Check early, then decide at 4 weeksAsk about side effects within 2 weeks. Less than 20% improvement in the symptom score by 2 to 4 weeks predicts failure: by 4 weeks, consider raising the dose or switching. Response is a drop of 50% or more; remission is a PHQ-9 score of 4 or less.
  8. Not better: switch or addNo response or poor tolerance: switch to another first-line antidepressant, or to CBT. Partial response that is well tolerated: add an adjunct (first-line aripiprazole or brexpiprazole) or add CBT. Failure of 2 or more adequate trials is treatment-resistant depression: recheck the diagnosis, then consider rTMS, esketamine nasal spray with an oral antidepressant, or ECT.
  9. After remission, continue, then taperKeep the antidepressant for 6 to 12 months after remission, or 2 years or more with risk factors for recurrence such as residual symptoms, many prior episodes or chronic episodes. Taper over weeks to months; fluoxetine needs no taper, and paroxetine and venlafaxine carry the highest risk of discontinuation symptoms.

Guidelines differ on step 9: the APA 2010 guideline advises 4 to 9 months of continuation, with maintenance after 3 or more episodes; this post follows the newer CANMAT 2023 range of 6 to 12 months.

Clue in the stem, next best step

Clue in the stemWhat it points toNext best step
Five depressive symptoms for 3 weeks, mild impairment, no suicidal ideationMild MDDPsychotherapy such as CBT
Depressed now, but last year a week of little sleep, racing thoughts and overspendingBipolar disorder, not MDDNo antidepressant alone; use mood-stabilizing treatment
Suicidal ideation with a plan and intent to actHigh suicide riskInpatient care
Delusions of guilt, voices saying he deserves to dieMDD with psychotic featuresAntidepressant plus antipsychotic, or ECT
Mute, posturing, refusing food and fluidsCatatonic features with physical declineECT, or a benzodiazepine for the catatonia
Sertraline for 4 weeks, symptom score down only 10%No early improvementRaise the dose, or switch if side effects limit it
Low libido and delayed orgasm on an SSRISSRI sexual side effectSwitch to an agent with fewer sexual effects, such as bupropion
Partial response at a full dose, no side effectsPartial responseAdd aripiprazole or brexpiprazole, or add CBT
Insomnia, poor appetite and weight lossSymptoms that favor a sedating agentConsider mirtazapine

Where students lose points

  • Starting an SSRI before asking about mania or hypomania. A past manic episode makes it bipolar I, where antidepressant monotherapy should be avoided.
  • Calling a drug a failure after 1 or 2 weeks. SSRIs may take up to 6 weeks for full effect; the dose-or-switch decision comes at about 4 weeks.
  • Choosing a TCA for a patient at risk of overdose. TCAs cause altered mental status, cardiac toxicity and seizures in overdose; SSRIs are preferred.
  • Giving bupropion to a patient with bulimia, anorexia or a seizure disorder. It lowers the seizure threshold.
  • Stopping the antidepressant as soon as the patient feels well, or stopping it abruptly. Continue for 6 to 12 months after remission, then taper.
  • Forgetting the boxed warning. Antidepressants carry an FDA warning for suicidality in patients under 25, so monitor them closely after starting.

Practice question

A 29-year-old woman comes to the clinic with 6 weeks of low mood, loss of interest in her hobbies, poor concentration, fatigue and early morning awakening. She feels worthless but has no thoughts of death or suicide. She has never had a period of elevated mood or decreased need for sleep. She smokes 1 pack of cigarettes daily and wants to quit. During an earlier episode 3 years ago, she stopped an antidepressant because of low libido and weight gain, and she asks for a medicine that avoids both. She has no history of seizures, head injury or an eating disorder and rarely drinks alcohol. Temperature is 36.8 C, blood pressure 118/76 mm Hg, pulse 76/min and BMI 23 kg/m². Examination is normal. Hemoglobin is 13.4 g/dL, TSH 1.9 µU/mL and sodium 139 mEq/L; a urine toxicology screen is negative. Her PHQ-9 score is 16. She is offered CBT but prefers medication.

Which of the following is the most appropriate pharmacotherapy?

  1. Bupropion
  2. Mirtazapine
  3. Paroxetine
  4. Amitriptyline
  5. Phenelzine
Show the answer

Answer: A. She has MDD with no history of mania and no safety concerns, so a second-generation antidepressant is a first-line choice. Bupropion is one of the few antidepressants without sexual dysfunction, can cause weight loss, and is approved for smoking cessation. She has none of its contraindications: no seizure disorder, no bulimia or anorexia, and no alcohol withdrawal.

Why the others are wrong. B: mirtazapine has fewer sexual side effects but increases appetite and weight and causes drowsiness. C: paroxetine is an SSRI; sexual dysfunction and weight change are common, and it has a high risk of discontinuation symptoms. D: amitriptyline is a TCA, a second-line choice that is dangerous in overdose. E: phenelzine is an MAOI, a third-line choice with tyramine and drug interactions that can cause hypertensive crisis or serotonin syndrome.

60-second recall

  • Time criterion for MDD – at least 2 weeks, with depressed mood or loss of interest among 5 or more symptoms.
  • Preferred first treatment for mild MDD – structured psychotherapy such as CBT.
  • No early improvement means – less than 20% drop in the symptom score by 2 to 4 weeks.
  • First-line adjuncts for a partial response (CANMAT) – aripiprazole or brexpiprazole.
  • How long to continue after remission – 6 to 12 months; 2 years or more with risk factors.

Next: browse every Shelf Prep post, review the hyponatremia algorithm (SSRIs and SNRIs raise the risk of hyponatremia in adults over 65), present a case with MedRise Viva, or see MedRise for students.

Sources

MedRise Shelf Prep is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.

Book a free strategy call

Ten minutes to look at your exam date, your scores and what is getting in the way.